Comparison of ABC transporter modulation by atazanavir in lymphocytes and human brain endothelial cells: ABC transporters are involved in the atazanavir-limited passage across an in vitro human model of the blood-brain barrier

AIDS Research and Human Retroviruses

Volumn 24, Issue 9, 2008, Pages 1147-1154

  Bousquet, Laurence ^a,b   Roucairol, Camille ^a,c   Hembury, Alexandra ^a   Nevers, Marie Claire ^a   Creminon, Christophe ^a   Farinotti, Robert ^b,d   Mabondzo, Aloïse ^a  

^a SERVICE DE CHIMIE BIOORGANIQUE ET DE MARQUAGE   (France)

^b UNIVERSITÉ PARIS SACLAY   (France)

^c UNIVERSITÉ CÔTE D'AZUR   (France)

^d ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ABC TRANSPORTER; ATAZANAVIR; FLUORESCENT DYE; GLYCOPROTEIN P; MULTIDRUG RESISTANCE PROTEIN 1;

ARTICLE; BLOOD BRAIN BARRIER; CENTRAL NERVOUS SYSTEM; COCULTURE; CONTROLLED STUDY; DRUG EFFICACY; DRUG PROTEIN BINDING; DRUG TRANSPORT; EFFUSION; ENDOTHELIUM CELL; ENZYME ACTIVATION; FETUS; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE; IMMUNOMODULATION; IN VITRO STUDY; INCUBATION TIME; LYMPHOCYTE; NORMAL HUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN INTERACTION; UPREGULATION;

ATP-BINDING CASSETTE TRANSPORTERS; BLOOD-BRAIN BARRIER; BRAIN; CELLS, CULTURED; ENDOTHELIAL CELLS; FLUORESCENT DYES; GENE EXPRESSION PROFILING; HIV PROTEASE INHIBITORS; HUMANS; LYMPHOCYTES; MICROSCOPY, FLUORESCENCE; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; OLIGOPEPTIDES; P-GLYCOPROTEIN; PYRIDINES;

EID: 51849102959     PISSN: 08892229     EISSN: None     Source Type: Journal    
DOI: 10.1089/aid.2007.0022     Document Type: Article

References (37)

1. Eisenblatter T, Huwel S, and Galla HJ: Characterisation of the brain multidrug resistance protein (BMDP/ABCG2/BCRP) expressed at the blood-brain barrier. Brain Res 2003;971(2):221-231.
2. Lipton SA and Gendelman HE: Seminars in medicine of the Beth Israel Hospital, Boston. Dementia associated with the acquired immunodeficiency syndrome. N Engl J Med 1995;332(14):934-940.
3. Choo EF, Leake B, Wandel C, et al.: Pharmacological inhibition of P-glycoprotein transport enhances the distribution of HIV-1 protease inhibitors into brain and testes. Drug Metab Dispos 2000;28(6):655-660.
4. Cordon-Cardo C, O'Brien JP, Casals D et al.: Multidrug-resistance gene (P-glycoprotein) is expressed by endothelial cells at blood-brain barrier sites. Proc Natl Acad Sci USA 1989;86(2):695-698.
5. Huisman MT, Smit JW, Wiltshire HR, et al.: P-glycoprotein limits oral availability, brain, and fetal penetration of saquinavir even with high doses of ritonavir. Mol Pharmacol 2001;59(4):806-813.
6. Kim RB, Fromm MF, Wandel C, et al.: The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors. J Clin Invest 1998;101(2):289-294.
7. Black PH: HTLV-III, AIDS, and the brain. N Engl J Med 1985;313(24):1538-1540.
8. Litman T, Druley TE, Stein WD, and Bates SE: From MDR to MXR: New understanding of multidrug resistance systems, their properties and clinical significance. Cell Mol Life Sci 2001;58(7):931-959.
9. Seelig A, Blatter XL, and Wohnsland F: Substrate recognition by P-glycoprotein and the multidrug resistance-associated protein MRP1: A comparison. Int J Clin Pharmacol Ther 2000;38(3):111-121.
10. Perloff MD, Von Moltke LL, Marchand JE, and Greenblatt DJ: Ritonavir induces P-glycoprotein expression, multidrug resistance-associated protein (MRP1) expression, and drug transporter-mediated activity in a human intestinal cell line. J Pharm Sci 2001;90(11):1829-1837.
11. Vishnuvardhan D, Moltke LL, Richert C, and Greenblatt DJ: Lopinavir: Acute exposure inhibits P-glycoprotein; extended exposure induces P-glycoprotein. AIDS 2003;17(7):1092-1094.
12. Perloff MD, Von Moltke LL, Fahey JM, and Greenblatt DJ: Induction of P-glycoprotein expression and activity by ritonavir in bovine brain microvessel endothelial cells. J Pharm Pharmacol 2007;59(7):947-953.
13. Chandler B, Almond L, Ford J, et al.: The effects of protease inhibitors and nonnucleoside reverse transcriptase inhibitors on P-glycoprotein expression in peripheral blood mononuclear cells in vitro. J Acquir Immune Defic Syndr 2003;33(5):551-556.
14. Ford J, Meaden ER, Hoggard PG, et al.: Effect of protease inhibitor-containing regimens on lymphocyte multidrug resistance transporter expression. J Antimicrob Chemother 2003;52(3):354-358.
15. Huisman MT, Smit JW, Crommentuyn KM, et al.: Multidrug resistance protein 2 (MRP2) transports HIV protease inhibitors, and transport can be enhanced by other drugs. AIDS 2002;16(17):2295-2301.
16. Gupta A, Zhang Y, Unadkat JD, and Mao Q: HIV protease inhibitors are inhibitors but not substrates of the human breast cancer resistance protein (BCRP/ABCG2). J Pharmacol Exp Ther 2004;310(1):334-341.
17. Weiss J, Rose J, Storch CH, et al.: Modulation of human BCRP (ABCG2) activity by anti-HIV drugs. J Antimicrob Chemother 2007;59(2):238-245.
18. Perloff ES, Duan SX, Skolnik PR, Greenblatt DJ, and Von Moltke LL: Atazanavir: Effects on P-glycoprotein transport and CYP3A metabolism in vitro. Drug Metab Dispos 2005;33(6):764-770.
19. Chinn LW, Gow JM, Tse MM, Becker SL, and Kroetz DL: Interindividual variability in the effect of atazanavir and saquinavir on the expression of lymphocyte P-glycoprotein. J Antimicrob Chemother 2007;60(1):61-67.
20. Lucia MB, Golotta C, Rutella S, et al.: Atazanavir inhibits P-glycoprotein and multidrug resistance-associated protein efflux activity. J Acquir Immune Defic Syndr 2005;39(5):635-637.
21. Josserand V, Pelerin H, Bruin B, et al.: Evaluation of drug penetration into the brain: A double study by in vivo imaging with positron emission tomography and using an in vitro model of the human blood-brain barrier. J Pharmacol Exp Ther 2006;316(1):79-86.
22. Megard I, Garrigues A, Orlowski S, et al.: A co-culture-based model of human blood-brain barrier: Application to active transport of indinavir and in vivo-in vitro correlation. Brain Res 2002;927(2):153-167.
23. Meaden ER, Hoggard PG, Khoo SH, and Back DJ: Determination of P-gp and MRP1 expression and function in peripheral blood mononuclear cells in vivo. J Immunol Methods 2002;262(1-2):159-165.
24. Fernetti C, Pascolo L, Podda E, et al.: Preparation of an antibody recognizing both human and rodent MRP1. Biochem Biophys Res Commun 2001;288(4):1064-1068.
25. Storch CH, Theile D, Lindenmaier H, Haefeli WE, and Weiss J: Comparison of the inhibitory activity of anti-HIV drugs on P-glycoprotein. Biochem Pharmacol 2007;73(10):1573-1581.
26. Legrand O, Simonin G, Perrot JY, Zittoun R, and Marie JP: Pgp and MRP activities using calcein-AM are prognostic factors in adult acute myeloid leukemia patients. Blood 1998;91(12):4480-4488.
27. Gekeler V, Ise W, Sanders KH, Ulrich WR, and Beck J: The leukotriene LTD4 receptor antagonist MK571 specifically modulates MRP associated multidrug resistance. Biochem Biophys Res Commun 1995;208(1):345-352.
28. Rautio J, Humphreys JE, Webster LO, et al.: In vitro P-glycoprotein inhibition assays for assessment of clinical drug interaction potential of new drug candidates: A recommendation for probe substrates. Drug Metab Dispos 2006;34(5):786-792.
29. Allen JD, van LA, Lakhai JM, et al.: Potent and specific inhibition of the breast cancer resistance protein multidrug transporter in vitro and in mouse intestine by a novel analogue of fumitremorgin C. Mol Cancer Ther 2002;1(6):417-425.
30. Sadanand V, Kankesan J, Yusuf A, et al.: Effect of PSC 833, a potent inhibitor of P-glycoprotein, on the growth of astrocytoma cells in vitro. Cancer Lett 2003;198(1):21-27.
31. Roucairol C, Azoulay S, Nevers MC, et al.: Quantitative immunoassay to measure plasma and intracellular atazanavir levels: Analysis of drug accumulation in cultured T cells. Antimicrob Agents Chemother 2007;51(2):405-411.
32. Solon EG, Balani SK, Luo G, et al.: Interaction of ritonavir on tissue distribution of a [(14)C]L-valinamide, a potent human immunodeficiency virus-1 protease inhibitor, in rats using quantitative whole-body autoradiography. Drug Metab Dispos 2002;30(11):1164-1169.
33. Anthonypillai C, Gibbs JE, and Thomas SA: The distribution of the anti-HIV drug, tenofovir (PMPA), into the brain, CSF and choroid plexuses. Cerebrospinal Fluid Res 2006;3:1.
34. Goldsmith DR and Perry CM: Atazanavir. Drugs 2003;63(16):1679-1693.
35. Taburet AM, Piketty C, Chazallon C, et al.: Interactions between atazanavir-ritonavir and tenofovir in heavily pretreated human immunodeficiency virus-infected patients. Antimicrob Agents Chemother 2004;48(6):2091-2096.
36. Bauer B, Hartz AM, Fricker G, and Miller DS: Pregnane X receptor up-regulation of P-glycoprotein expression and transport function at the blood-brain barrier. Mol Pharmacol 2004;66(3):413-419.
37. Siest G, Jeannesson E, Marteau JB, et al.: Transcription factors and drug metabolizing enzymes genes expression in lymphocytes from human healthy subjects. Drug Metab Dispos 2008;36(1):182-189.